Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 3Phase 1 1

Status

Completed 63Active not recruiting 24Terminated 6Recruiting 5Unknown 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 3Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Genitourinary 1Endocrine 1

Conditions

von Hippel-Lindau Disease 1Pheochromocytoma 1Paraganglioma 1Neuroblastoma 1Multiple Myeloma 1Metastatic Urothelial Cancer 1Low-grade Glioma 1Hematologic Neoplasms 1Adenoma, Islet Cell 1

Interventions

zimberelimab 1tovorafenib 1talquetamab 1sacituzumab govitecan 1pembrolizumab 1naxitamab 1enfortumab vedotin 1belzutifan 1avelumab 1Granulocyte-Macrophage Colony-Stimulating Factor 1Gemcitabine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Has announcements × Clear all
NCT04634552 2026-06-05

MonumenTAL-1

Janssen Research & Development, LLC

Phase 2 Recruiting
510 enrolled 1 FDA
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT04924075 2026-05-28

MK-6482-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting
322 enrolled 1 FDA
CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting
827 enrolled 1 FDA
Genitourinary

Metastatic Urothelial Cancer

NCT03363373 2026-02-19

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Y-mAbs Therapeutics

Phase 2 Recruiting
122 enrolled 1 FDA
CNS

Neuroblastoma

NCT04775485 2025-04-10

FIREFLY-1

Day One Biopharmaceuticals, Inc.

Phase 2 Recruiting
141 enrolled 1 FDA
CNSOther solid neoplasm

Low-grade Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡